How to detect and manage immunotherapy toxicity

ESGO eAcademy, Domenica Lorusso, 287978

Checkpoint inhibitors in gynaecological cancers: What are the data?

ESGO eAcademy, Christian Marth, 287977

The development of checkpoint inhibitor combinations: Which future?

ESGO eAcademy, Eric Lauraine, 287976

Immunotherapy in gynae-oncology: Why and how?

ESGO eAcademy, Lana Kandalaft, 287975

e-Module ERAS

ESGO eAcademy, Course Faculty, 287974

e-Module ERAS

ESGO eAcademy, Course Faculty, 370145

Enhanced Recovery Hospital Implementation Process (ERAS): A holistic approach

ESGO eAcademy, Pedro Ramirez, 287973

Pre- and postoperative care: Focusing on nutrition and immunonutrition

ESGO eAcademy, Annamaria Ferrero, 287972

Perioperative anaesthetic management

ESGO eAcademy, Carolyn Weiniger, 287971

The role of the Intensive Care Unit (ICU) in postoperative management

ESGO eAcademy, Nikolaos Thomakos, 287970

Minimally-invasive cytoreduction in recurrent endometrial cancer: laparoscopic and uniportal video-assisted thoracoscopic surgery (VATS) combined approach

ESGO eAcademy, Nicolo Bizzarri, 287843

Very advanced disease (fistula)

ESGO eAcademy, Fabio Landoni, 293432

Radical treatment in early metastatic disease?

ESGO eAcademy, Elzbieta van der Steen-Banasik, 293417

Pregnancy, metastatic disease, very advanced disease (fistula)

ESGO eAcademy, Alexandros Rodolakis, 293438

Chemotherapy in recurrent/metastatic disease setting

ESGO eAcademy, Mary McCormack, 293423

Is there a place for re-irradiation?

ESGO eAcademy, Cyrus Chargari, 293424

Place, indications and modalities of pelvic exenterations and laterally extended surgery (+/- IORT/BT)

ESGO eAcademy, Alexandros Rodolakis, 293437

Management of pelvic recurrent disease in non-irradiated area

ESGO eAcademy, Elzbieta van der Steen-Banasik, 293416

Place, modalities and reasons of neoadjuvant Chemo

ESGO eAcademy, Mary McCormack, 293422

Availability of high-quality surgery around the world

ESGO eAcademy, Alexandros Rodolakis, 293436

What if I have no access to high quality radiotherapy (IMRT, MRI-guided brachy)?

ESGO eAcademy, Elzbieta van der Steen-Banasik, 293418

ESGO/ESTRO/ESP Guidelines

ESGO eAcademy, David Cibula, 293428

Nodal involvement

ESGO eAcademy, Remi Nout, 293421

Local tumor extension: depth of invasion / parametrial infiltration / vaginal involvement

ESGO eAcademy, David Cibula, 293427

Morbidity of (adjuvant) CT/RT and impact on QoL

ESGO eAcademy, Remi Nout, 293420

History of gynaecological radiotherapy

ESGO eAcademy, Elzbieta van der Steen-Banasik, 293415

Quality indicators of the radical surgery if performed in LACC, ESGO Recommendations

ESGO eAcademy, David Cibula, 293426

Clear contra-indications of the pelvic radical surgery in LACCC

ESGO eAcademy, Fabio Landoni, 293431

Role of TMB and best practice examples

ESGO eAcademy, Remi Nout, 293419

The role of ultrasound

ESGO eAcademy, David Cibula, 293425

How to select patients for a curative treatment: radiological and/or surgical staging?

ESGO eAcademy, Philippe Morice, 293414

Role of multidisciplinary team in staging of cervical cancer

ESGO eAcademy, Philippe Morice, 293413

Gynaecological examination and reporting (incl. colposcopy and ultrasound)

ESGO eAcademy, Alexandros Rodolakis, 293435

From FIGO to TNM

ESGO eAcademy, Christina Fotopoulou, 293430

Accessibility to different treatments around the world

ESGO eAcademy, Murat Gultekin, 293434

Cervical cancer carcinogenesis

ESGO eAcademy, Christina Fotopoulou, 293429

Epidemiology of HPV and cervical cancer, a worldwide problem

ESGO eAcademy, Murat Gultekin, 293433

The place of robotic-assisted surgery in an Enhanced Recovery program

ESGO eAcademy, Eric Lambaudie, 287835

Principles of Writing a Good Scientific Manuscript

ESGO eAcademy, Pedro Ramirez, 286732

Breaking bad news: What, as doctors, can we do better?

ESGO eAcademy, Jalid Sehouli, 282885

The patient's perspective

ESGO eAcademy, Charo Hierro, 282879

The medical oncologist's perspective

ESGO eAcademy, Jonathan Ledermann, 282878

What do patients need to improve their QoL?

ESGO eAcademy, Esra Urkmez, 282884

The gynaeco-oncologist's perspective

ESGO eAcademy, Denis Querleu, 282877

The clinical geneticist's perspective

ESGO eAcademy, Emmanouil Saloustros, 282876

The clinical scientist's perspective

ESGO eAcademy, Gourley Charlie, 282875

The pathologist's perspective

ESGO eAcademy, Xavier Matias-Guiu, 282874

How to assess PROs and quality of life?

ESGO eAcademy, Florence Joly, 282882

Medical treatment and update on recent molecular studies in mucinous ovarian cancer

ESGO eAcademy, Alexandra Leary, 282871

New insights into surgical management of mucinous ovarian cancer

ESGO eAcademy, Philippe Morice, 282870

PRO

ESGO eAcademy, Ingfrid Haldorsen, 282866

Restrictions in the histopathological diagnosis of mucinous ovarian carcinoma

ESGO eAcademy, Aikaterini Pavlaki, 282869

Medicamentous risk-reducing strategies after sporadic gynaecological malignancies

ESGO eAcademy, Cristiana Sessa, 282859

Chemotherapy and molecular prognostic significance in locally advanced vulvar cancer

ESGO eAcademy, Muieddine Seoud, 282864

Medicamentous risk-reducing management in BRCA mutation carriers

ESGO eAcademy, Shani Paluch-Shimon, 282858

Radiation therapy in the treatment of locally advanced vulvar cancer

ESGO eAcademy, Anuja Jhingran, 282863

Surgical risk-reducing strategies in BRCA mutation carriers

ESGO eAcademy, Pauline Wimberger, 282857

Surgery in the treatment of locally advanced vulvar cancer

ESGO eAcademy, Fuat Demirkiran, 282862

Lesser sack, porta hepatis, and celiac trunk

ESGO eAcademy, Cagatay Taskiran, 282854

The microbiome, carcinogenesis, and prognosis: Driver or passenger?

ESGO eAcademy, Julien Marchesi, 282848

Splenectomy, distal pancreatectomy, and partial gastrectomy

ESGO eAcademy, Pawel Knapp, 282853

The vaginal microbiome, HPV infection, and progression of cervical disease

ESGO eAcademy, Murat Gultekin, 282847

Assessment of resectability: Imaging and/or laparoscopy

ESGO eAcademy, Anna Fagotti, 282851

Carcinogenesis and prognosis in gynaecological cancers: Is this microbiome-related?

ESGO eAcademy, Maria Kyrgiou, 282846

Case presentation of foetal and neonatal follow-up during and after chemo during pregnancy

ESGO eAcademy, Monica Fumagalli, 282843

Adding translational research in Gyn Cancer trials

ESGO eAcademy, Sandro Pignata, 282838

Case presentation of cervical cancer during pregnancy

ESGO eAcademy, Frederic Amant, 282842

Innovation in endometrial cancer and cervical cancer

ESGO eAcademy, Antonio Gonzalez Martin, 282837

Case presentation of breast cancer during pregnancy

ESGO eAcademy, Michael Halaska, 282841

Innovation in ovarian cancer

ESGO eAcademy, Isabelle Ray-Coquard, 282836

Advances in techniques for external beam radiotherapy and brachytherapy in cervical cancer

ESGO eAcademy, Jacob Lindegaard, 282833

The way forward: Novel agents in development

ESGO eAcademy, Ros Glasspool, 282828

Achieving better local control with less toxicity through evidence-based planning aims and dose volume constraints

ESGO eAcademy, Christian Kirisits, 282832

Novel targets: A molecular perspective

ESGO eAcademy, Viola Heinzelmann-Schwarz, 282827

Radiotherapy in cervical cancer, where do we come from? Where are we now? Where are we going?

ESGO eAcademy, Elzbieta van der Steen-Banasik, 282831

Parallel session 21: Platinum-resistant ovarian cancer: A new definition and novel approaches in a changing landscape

ESGO eAcademy, Antonio Gonzalez Martin, 282825

Sex cord stromal tumours in adolescents

ESGO eAcademy, Dominik Schneider, 282818

The role of immunotherapy in GTN

ESGO eAcademy, Ulrika Joneborg, 282823

Germ cell tumours in adolescents

ESGO eAcademy, Philippe Morice, 282817

How to manage placental site nodules, PSTT, and ETT

ESGO eAcademy, Michael Seckl, 282822

Specificities of treating cancers in adolescents

ESGO eAcademy, Gabriele Calaminus, 282816

The key ingredients for a successful GTD centre

ESGO eAcademy, Christianne Lok, 282821

Novel combinations in ovarian cancer

ESGO eAcademy, Johanna Maenpaa, 282813

Systemic molecular targeted therapies: Achievements and prospects

ESGO eAcademy, Jonathan Ledermann, 282807

Novel targeted drugs in endometrial cancer

ESGO eAcademy, Faculty / Presenters, 282812

MRI Guided Brachytherapy: Evolution and challenges

ESGO eAcademy, Johannes Dimopoulos, 282806

Emerging targeted therapies in cervical cancer

ESGO eAcademy, Ana Oaknin, 282811

Technological developments in surgery and the contribution of robotic surgery

ESGO eAcademy, Rainer Kimmig, 282805

DNA repair interfering therapies

ESGO eAcademy, Nicole Concin, 282810

Vaccination: Achievements and challenges

ESGO eAcademy, Elmar Joura, 282804

Introduction Uzi Beller Award

ESGO eAcademy, Pedro Ramirez, 282799

Best translational research - Helga Salvesen Award

ESGO eAcademy, George Coukos, 282798

Introduction Helga Salvesen award

ESGO eAcademy, Cristiana Sessa, 282797

The role of immunotherapy in the management of gynecological cancers

ESGO eAcademy, Meletios Dimopoulos, 282796

Is the new endometrial cancer classification ready for prime time?

ESGO eAcademy, Carien Creutzberg, 282794

Is there a role for immunotherapy in endometrial cancer?

ESGO eAcademy, Sandro Pignata, 282793

Is cytoreduction an option in advanced endometrial cancer

ESGO eAcademy, Elena Ulrikh, 282792

Chemotherapy in advanced endometrial cancer

ESGO eAcademy, Aristotelis Bamias, 282791

Trophoblastic diseases

ESGO eAcademy, Michael Seckl, 290423

Ovarian clear cell carcinoma

ESGO eAcademy, Antonio Gonzalez Martin, 290422